The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels

Circulating cell-free DNA is associated with cardiometabolic risk factors: The Health 2000 Survey

(2014) Juulia Jylhävä et al.   ATHEROSCLEROSIS

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

(2013) Kenneth W. Mahaffey et al.   AMERICAN HEART JOURNAL

Elevated level of cell-free plasma DNA is associated with advanced-stage breast cancer and metastasis

(2013) Carmela Nicolini et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents

(2013) Valderilio Feijó Azevedo et al.   RHEUMATOLOGY INTERNATIONAL

Activation of Peroxisome Proliferator-Activated Receptorγby Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1

(2012) Jung Seok Hwang et al.   MEDIATORS OF INFLAMMATION

Plasma Cell-Free DNA Levels Are Elevated in Acute Puumala Hantavirus Infection

(2012) Tuula K. Outinen et al.   PLoS One

Circulating Cell-Free DNA

(2012) Sarah Breitbach et al.   SPORTS MEDICINE

Rosiglitazone does not improve vascular function in subjects with chronic kidney disease

(2011) D. T. Chan et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Apoptotic cell-free DNA promotes inflammation in haemodialysis patients

(2011) J. Atamaniuk et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Fatal Outcome in Bacteremia is Characterized by High Plasma Cell Free DNA Concentration and Apoptotic DNA Fragmentation: A Prospective Cohort Study

(2011) Reetta Huttunen et al.   PLoS One

Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas

(2009) S. Hohaus et al.   ANNALS OF ONCOLOGY

Cell-Free Plasma DNA during Peritoneal Dialysis and Hemodialysis and in Patients with Chronic Kidney Disease

(2009) Marie Korabecna et al.   Annals of the New York Academy of Sciences

Use of Peroxisome Proliferator‐Activated Receptor γ Agonists as Adjunctive Treatment forPlasmodium falciparumMalaria: A Randomized, Double‐Blind, Placebo‐Controlled Trial

(2009) Andrea K. Boggild et al.   CLINICAL INFECTIOUS DISEASES

Comparison of Circulating Plasma DNA Levels between Lung Cancer Patients and Healthy Controls

(2009) Kyong-Ah Yoon et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

(2008) Sudarshan K. Vijay et al.   ACTA DIABETOLOGICA

Von Willebrand Factor in Cardiovascular Disease

(2008) Alexander O. Spiel et al.   CIRCULATION

Cell-Free Plasma DNA as a Predictor of Outcome in Severe Sepsis and Septic Shock

(2008) K. Saukkonen et al.   CLINICAL CHEMISTRY

Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation

(2008) E. Linden et al.   Clinical Journal of the American Society of Nephrology